	U.S. Patent and red to respond to a collection of i	Approved for use through 07/31/20 Trademark Office; U.S. DEPARTME formation unless it contains a valid 0	NT OF COMMERCE
Request for Continued Examination (RCE) Transmittal Address to: Mail Stop RCE Commissioner for Patents P.O. 80x 1450 Alexandria, VA 22313-1450	Application Number	10/587,767	
	Filing Date	October 17, 2006	
	First Named Inventor	Lene Moller	
	Art Unit	1656	
	Examiner Name	Marsha M. Tsay	
	Attorney Docket Num	per 13323-105002	
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant applica			
Submission required under 37 CFR 1.114] Note: If the RCE in proper, any previously filed unentaned amendments and amendments endozed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). a. Previously submitted. It is final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. If Consider the arguments in the Appeal Brief or Repty Brief previously filed on			
b.	****	nation Disclosure Statement (ID: Petition for Extension of Time	1
Suspension of ection on the above-identified application is requested under 37 CFR 1 103(c) for a a			
Fees] The RCC fee under 37 CPR 1.17(e) is required by 37 CPR 1.114 when the RCE is filed. Deposit Account No.			
i			
b. Check in the amount of \$enclosed			
c Payment by credit card (Form PTC-2038 enclosed)			
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Signature /mschaet willis/ Name (Print/Typs) #&chaet & M/Rise		Date March 31, 2 Registration No. 53,913	2009
A MICHELLY AT TAINS	THAT WO OF TRAVE	100,010	
I honeby centify that this correspondence is twenty deposited with the United States Potal Service with undicaret proteings as first class made in an envelope addressed to Mail Stop RCE. Ourninesence for Patents, P.O. Box 1450. Abcondrin, VA 22313-1450 or facularity transmitted to the U.S. Patent and Tradomer's Office on the date storm below.			
Signature Name (Print/Type)		Date	
(491110 ft. com : Abra)			

The collection of information is required by 37 CFR. 1141. The information are required to obtain or retain a locality by en public writing as the latest by the CEPTO to proceed an application of confidencing with a local post of the confidencing and a local post of the confidencing of

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Instruction Sheet for RCEs

(not to be submitted to the USPTO)

NOTES:

An RCE is not a new application, and filing an RCE will not result in an application being accorded a new filing date.

Filing Qualifications:

The application must be a utility or piant application filed on or after June 8, 1995. The application cannot be a provisional application, a utility or piant application filed before June 8, 1995, a design application, or a patent under reexamination. See 37 CFR 1.114(a).

Filing Requirements:

Prosecution in the application must be closed. Prosecution is closed if the applicat ion is under appeal, or the last Office action is a final action, a notice of allowance, or an action that otherwise closes prosecution in the application (e.g., an Office action under Exparte Quayle). See 37 CPR 114(b).

A submission and a fee are required at the time the RCE is filed. If reply to an Office action under 35 U.S.C. 132 is outstanding (e.g., the application is under final rejection), the submission must meet the reply requirements of 37 CFR 1.111. If there is no outstanding Office action, the submission can be an information disclosure statement, an amendment, rew arguments, or new evidence. See 37 CFR 1.114(c). The submission may be a previously filed amendment (e.g., an amendment after final rejection).

WARNINGS:

Request for Suspension of Action:

All RCE filing requirements must be met before suspension of action is granted. A request for a suspension of action under 37 CFR 1.103(c) does <u>not</u> satisfy the submission requirement and does not permit the filing of the required submission to be suspended.

Improper RCE will NOT toll Any Time Period:

Before Appeal - If the RCE is improper (e.g., prosecution in the application is not closed or the submission or fee has not been filed) and the application is not under appeal, the time period set forth in the last Office action will continue to run and the application will be abandoned after the statutory time period has expired if a reply to the Office action is not timely filed. No additional time will be given to correct the improper RCE.

Under Appeal - If the RCE is improper (e.g., the submission or the fee has not been filed) and the application is under appeal, the improper RCE is effective to withdraw the appeal. Withdrawal of the appeal results in his allowance or abandonment of the application depending on the status of the claims, if there are no allowed claims, the application is abandoned. If there is at least one allowed claim, the application will be passed to issue on the allowed claim(s). See MPEP 1215.01.

See MPEP 706.07(h) for further information on the RCE practice.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attended form related to a patient application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent, if you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or ebandomment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S. C. 552) and the Privacy Act (6 U.S. C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, nagistrate, or administrative irribunat, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, bursuant to 5 U.S.C. 552(aft).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator. General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filted in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.